Global healthcare today is a huge profitable market, with pharmaceutical companies being at the top of the food chain in terms of global revenue. As most of you will know there’s a vast range of medical disorders and clinical illnesses such as cardiovascular and neurodegenerative diseases that astonishingly effects over one billion people worldwide. In result, innovative medical and pharmaceutical companies are constantly engineering and creating new treatments.

However the problem lies within achieving the results and the process in doing so. The most widely and adverse methods are clinical trials to the public, where treatment reacts differently to each subject depending on their genetics. The down falls can include inaccurate test results, major or minor side effects and a long drawn out process with the end result of no conclusion.

The Revolution

Up until recently, DNA sequencing was extremely expensive but now more and more pharmaceuticals and medical companies are greatly benefiting from the study of genomic data. This data can be used to find new ways for the prevention, treatment and maybe even cures to multiple thousands of varied diseases and disorders. Not only can the data be used for medical breakthroughs, it can be used for knowledge of ancestors and to explore your family roots.

Our genomic data is specifically unique to each and everyone of us, therefore when this data is studied combined with thousands of other genetic data being cross examined. Medical professionals for example doctors and specialists can come to a better conclusion to what treatment is needed for an individual thus being tailor made for the best results.

Genomic and clinical data are still generally collected and studied in silos, many countries have put in place strict provisions guiding international sharing, and a few even prohibit it completely. Despite these limitations, increasing amounts of genomic data have been generated and become available from different sources. The institutions and corporations involved in this sharing, are basically selling people’s genomic data for huge profits, surely we have the right to own our genomic data and profit ourselves...

Shivom

This is where Shivom comes in, the next era of genomics and health care. Shivom offer services to patients and genome data donors that combine the two revolutionary technologies, blockchains and genomic data. This way everybody can have their genome sequenced and securely stored using the blockchain. This unique and innovative idea also means that the patients and genome data donors own their data and the access rights, they also have the choice to share their genomic data for a profit or reward. Patients get personalized health, well-being, and lifestyle information and they also receive access to ancestry information such as family trees.

The important part that the blockchain plays, is keeping the patients genomic data safe and secure. A public key is created for each patient which can be then encrypted and then shared if chosen to be, the patient has the right to the access and to whom they choose to share it with. The blockchain also makes it easier to share the information with stakeholders or in other cases keep certain stakeholders from accessing the info. it all gets better... medical and pharmaceutical companies will use the Shivom platform to refine drug development. By accessing the information shared by genome data donors the various companies will be able to achieve more accurate results in a more efficient way, benefiting both patients and the ecosystem.

A more dynamic ecosystem is created and constantly refined, in which the health and pharmaceutical community can identify and remove potential health roadblocks before they become serious. Genomic sequencing provides many benefits:
• Identifying the best course of care for patients with a particular condition
• Prevention of disease in healthy individuals
• Prediction of disease risk
• Disease diagnosis
• Treatment, including choice of most effective medication and dosage
• Disease prognosis
• Identifying new drug targets

Third party companies and providers will have the option to advertise their services and health/fitness apps through Shivom.

[Project Shivom] ()

TOPLINE NUMBERS
Global healthcare market USD$ 8.7 trillion by 2020
Deloitte 2017 global healthcare sector outlook
Precision medicine market CAGR 14.9% (2017-2025) USD$ 40 billion by end of 2016 CAGR 10-11% by 2025 — expected to reach up to 112.6 billion. This includes big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and more.
Precision Medicine Market Analysis & Trend - Therapeutics, Application- Forecast to 2025

The Tokens

The OmiX token enables buying, trading and other services. The token is the fuel of the Shivom ecosystem, as well as part of the governance of the system. There are many benefits of OmiX tokens which include premium services in the Shivom ecosystem, genome sequencing kits, sponsoring sequencing projects access to health/fitness apps from 3rd party providers, access to the genome database and the use of the tokens to pay donors for data/participation in research studies. Which makes it beneficial to both parties on either side of the fence.

Token distribution

Shivom will distribute 3 billion OmiX tokens

Token Sale
990M OmiX tokens will be sold during the ICO process.

Community
90M OmiX Tokens will be distributed to the community to grow and nurture the Shivom ecosystem, for bounty programs to leverage network effects, and for community initiatives to reward developers, entrepreneurs, and strategists.

Founders
420M OmiX will be allocated for founders to support the development of the Shivom ecosystem and their continued long-term alignment with the project.

Advisors
300M OmiX will be allocated for early backers and a global network of advisors.

Incentivizing Growth Pool
600M OmiX will be secured in a smart contract, allocated to the database, and introduced into circulation as rewards for data generation.

Company Reserve
600M OmiX will be kept by the Foundation as a reserve fund for future data contribution, running the Foundation and associated non-pro t R&D efforts. The Foundation maintains all authority to utilize a few or the majority of the reserve tokens for future external investors.